Zheng Xie

Practice Areas

Mr. Xie Zheng is a partner in the firm's Shanghai Office. His primary practice areas include banking and finance, M&A, restructuring and insolvency. He has practiced in these areas for more than 20 years. He also has extensive experience advising multinational companies and domestic chinese companies on labour and employment matters.

Career

Mr. Xie joined the firm as a partner in 2004. Before joining the firm, Xie Zheng worked at Clifford Chance LLP in Shanghai and London from 1996 to 2004.

Personal

Honors and Awards

Mr. Xie has been named a Leading Lawyer by Asia Law & Practice. He has also been named as a Leading PRC Lawyer in Banking and Finance and Corporate/M&A by Chambers & Partners.

Education

Experience

Banking and Finance:

-Advised a syndicate of banks led by China Merchants Bank in an acquisition loan of RMB 11.94 billion to a subsidiary of Guangzhou R&F Properties Co., Ltd. for its acquisition of 77 hotels from Dalian Wanda.

-Advised Prologis in a USD 97.8 million offshore loan facility and a RMB 60 million onshore loan facility with HSBC for the development and construction of onshore warehouse properties.

-Advised Prologis in offshore and onshore syndicate loan facility transactions with ING, BNPP and CRÉDIT AGRICOLE in amounts up to USD 250 million and RMB 100 million respectively for the development and construction of onshore warehouse properties.

-Advised the buyer group led by Mr. Zhou Hongyi in an RMB-equivalent USD 3 billion syndicated loan facility arranged by China Merchants Bank Co., Ltd., Shenzhen Branch for the privatization of Qihoo 360 Technology Co., Ltd.

-Advised Goldman Sachs in arranging and pre-funding a USD 450 million term loan facility granted to Biostime Healthy Australia Investment Pty Ltd. for refinancing a bridge acquisition loan facility used to acquire majority ownership of Swiss Wellness Group Pty Limited.

-Advised China Merchants Bank on three term loan facilities totaling HKD 27 billion granted to WD Knight I, WD Knight II and WD Knight III separately for the acquisition of all the H-shares of Dalian Wanda Commercial Properties Co., Ltd.

-Advised China Merchants Bank on a HKD 2.5 billion term loan facility granted to Xu’s Sport Company Limited for the privatization of Peak Sport Products Co., Limited.

-Advised a syndicate led by China Development Bank Hong Kong Branch, China Minsheng Banking Corp. Ltd. Hong Kong Branch, Bank of America, Citibank, Credit Suisse Singapore Branch, DBS, Deutsche Bank Hong Kong Branch and ICBC International in a USD 1.525 billion financing for the privatization of Focus Media Holding Limited (NASDAQ Code: FMCN).

-Advised CVC Asia Pacific Limited and its affiliates in USD 118 million of facilities arranged by JPMorgan Chase Bank, N.A., acting through its Hong Kong Branch, for the acquisition of an international education group.

-Advised Bank of China Macau Branch in a USD 320 million term loan facility granted to CDH Giant Health (HK) Limited for its acquisition of Fujian Nanping Nanfu Battery Co., Ltd.

M&A:

-Represented Bayer AG in connection with its acquisition of 100% shares in Dihon Pharmaceutical Group, a leading OTC and TCM maker in the China market.

-Represented Unilever in its acquisition of shares in Qinyuan Group Co., Ltd. a leading Chinese company engaged in water purifier and dispenser business.

-Represented Baxter on its investment in a leading Chinese parental nutrition products company.

-Represented Bayer on setting up and restructuring of various foreign investment enterprises in China.

-Represented CCMP/Unitas Capital on its acquisition of a leading Chinese environmental protection company.

-Represented Goldman Sachs PIA on equity investment in a leading Chinese shipbuilding company.

-Represented CapitaLand on restructuring of convertible bonds in aggregate principal amount of RMB 1,200,000,000 issued by Heng Yue Holdings Limited by acquiring a majority equity stake in Shenzhen Nanyou Shopping Park Project held by Heng Yue.

-Represented Pepsi on development of its Asia R&D and Logistic Centre project in Shanghai.

-Represented AstraZeneca on the development of a new drug manufacturing plant in China.

-Represented Marvell Semiconductor on its green field high-tech park project in Zhangjiang.

-Represented a variety of leading international private equity funds on growth capital or buy-out investment opportunities in China.

-Represented multinational corporations regularly in their PRC investments, including: establishing holding companies, wholly owned companies and joint venture companies; reorganizing their PRC operations; reorganizing their PRC operations; and handling issues related to government approvals, sales and distribution, labour and employment, foreign exchange control and land.

Restructuring and Insolvency:

-Represented a committee of financial creditors led by Bank of China, Jiangsu Branch on the debt restructuring of Yurun Group (雨润集团).

-Represented a committee of financial creditors led by Nanjing Bank and CITIC Bank on the debt restructuring of Sanpower Group (三胞集团).

-Represented a committee of financial creditors led by CITIC Bank on the debt restructuring of Fullshare Group (丰盛集团).

-Represented a group of syndicate lenders led by Citibank and their appointed administrative receivers (PwC) in relation to FerroChina’s insolvency proceeding, the creditors’ rights with the administrator of Changshu Everbright and other PRC subsidiaries of FerroChina, and the restructuring of Changshu Everbright.

-Represented a group of syndicate lenders in restructuring a USD 600 million facility to a PRC real estate development company.

-Represented a group of syndicate lenders led by Citibank in restructuring an RMB 3 billion facility to CIT’s subsidiary in China.